Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $30.20 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 4:30 PM 07/16/14 All times are local (Market data is delayed by at least 15 minutes).

alk-abello a/s-spon adr (AKABY) Snapshot

Open
--
Previous Close
$30.20
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
1.2B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
46.0M
EX-Date
03/25/15
P/E TM
--
Dividend
$0.15
Dividend Yield
0.63%
Current Stock Chart for ALK-ABELLO A/S-SPON ADR (AKABY)

Related News

No related news articles were found.

alk-abello a/s-spon adr (AKABY) Related Businessweek News

No Related Businessweek News Found

alk-abello a/s-spon adr (AKABY) Details

ALK-Abelló A/S, a pharmaceutical company, engages in the research and development, production, and sale of products for the diagnosis, prevention, and treatment of allergies worldwide. The company offers allergy immunotherapy products as injections, sublingual drops, and sublingual tablets for various allergies, including grass, ragweed, house dust mite, tree, cat, bee, and wasp. It also offers adrenaline auto-injectors for the treatment of severe allergic reactions. In addition, the company’s development programs include GRAZAX for grass allergic (ARC) and asthma prevention; GRASTEK for grass ARC; RAGWITEK for ragweed ARC; house dust mite (HDM) sublingual tablet-based allergy immunotherapy (SLIT)-tablets for HDM asthma and rhinitis; tree SLIT-tablet for tree ARC; and Japanese cedar SLIT-tablet for cedar tree ARC. It has strategic partnership agreements with Merck & Co., Inc. and Torii Pharmaceutical Co., Ltd. to develop, register, and commercialize SLIT-tablets in North America and Japan. The company was founded in 1923 and is headquartered in Hørsholm, Denmark.

1,844 Employees
Last Reported Date: 02/9/15
Founded in 1923

alk-abello a/s-spon adr (AKABY) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

alk-abello a/s-spon adr (AKABY) Key Developments

ALK-Abello A/S Approves Ordinary Dividend for 2014; Announces Executive Changes

ALK-Abello A/S approved ordinary dividend of DKK 5.00 per share at the annual general meeting held on 12 March 2015. The company also approved the appointment of Lars Holmqvist and Per Valstorp as new members of the Board of Directors. Christian Dyvig and Thorleif Krarup did not seek re-election. Lene Skole, who joined ALK's Board of Directors in 2014, was elected Vice Chairman of the Board of Directors.

ALK-Abelló A/S Presents at Carnegie Nordic Healthcare Seminar 2015, Mar-12-2015

ALK-Abelló A/S Presents at Carnegie Nordic Healthcare Seminar 2015, Mar-12-2015 . Venue: Regeringsgatan 56, Stockholm, Sweden.

ALK and Biocsl Enter into a Partnership

ALK and bioCSL announce a partnership in Australia and New Zealand which grants bioCSL exclusive rights to promote and sell ALK's SLIT-tablets against house dust mite and grass pollen allergy, and ALK's Jext(r) adrenaline auto-injector. ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK's sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as GRAZAX(r) in Europe and GRASTEK(r) in North America), and its adrenaline auto-injector, Jext(r). ALK will be responsible for product supply and bioCSL will undertake registration and commercialisation of the products. As part of the agreement, ALK will receive a minor upfront payment of an undisclosed amount, followed by a milestone payment upon approval of the HDM SLIT-tablet in Australia. ALK will sell products to bioCSL at a pre-agreed price structure ensuring a certain split of the final in-market revenues generated by bioCSL. The partnership with bioCSL advances ALK's strategy of broadening its geographical presence through partnerships, acquisitions or by establishing its own affiliates.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AKABY:US $30.20 USD 0.00

AKABY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergy Therapeutics PLC 22.00 GBp 0.00
DBV Technologies SA €46.24 EUR +0.38
Merck & Co Inc $59.86 USD +0.30
Sanofi €92.60 EUR +1.40
Stallergenes SA €54.88 EUR +0.48
View Industry Companies
 

Industry Analysis

AKABY

Industry Average

Valuation AKABY Industry Range
Price/Earnings 39.8x
Price/Sales 2.9x
Price/Book 3.0x
Price/Cash Flow 37.1x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALK-ABELLO A/S-SPON ADR, please visit www.alk-abello.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.